EMA issues advice on Lilly's bamlanivimab (LY-CoV555) alone and administered together with etesevimab (LY-CoV016) for the treatment of confirmed COVID-19 in the European Union

CHMP has completed a review of available data for both antibodies for the treatment of confirmed COVID-19 CHMP scientific opinion supports national decision-making within European Union (EU) member states on the use of the antibodies during a public health emergency before a formal marketing